Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

Which peptides are studied in relation to lipolysis?

A research-supply review of peptides and peptide-adjacent compounds examined in lipolysis research, spanning ghrelin, EPO, omentin-1, FGF21, myostatin and HSL endpoints, with notes on which findings are animal-only or in

peptides-pro Editorial

Lipolysis research draws on a set of peptide and peptide-adjacent analytes that are measured, manipulated or modelled in cell, animal and human studies. The compounds most frequently encountered in this literature include ghrelin (a 28-amino-acid stomach-derived orexigenic peptide), erythropoietin (EPO, a haematopoietic cytokine with reported non-haematopoietic metabolic activity), omentin-1 (an adipokine), fibroblast growth factor 21 (FGF21, a metabolic hormone), myostatin (MSTN, a myokine) and hormone-sensitive lipase (HSL, the enzyme rather than a peptide, but routinely paired with myostatin as a serum endpoint). Human chorionic gonadotropin (hCG) and insulin-like growth factor I (IGF-I) also appear in this space, largely through doping-control literature rather than mechanistic lipolysis work. Where the evidence block supplies identifiers, they are limited: ghrelin is described as a stomach-derived orexigenic peptide [3], and the remaining entries give class and tissue context rather than sequence, formula or molecular weight.

The mechanistic work centres on a small number of signalling axes: AMP-activated protein kinase (AMPK) and its downstream targets, the ghrelin system and its nutrient-sensing inputs, the erythropoietin receptor (EPOR) in adipose and skeletal muscle, and sympathetic-driven lipolysis downstream of central FGF21 induction.

Research Studies

Ghrelin and adipose lipolysis in alcohol-exposure models

Ghrelin normally rises during fasting and stimulates food intake. In the alcohol literature, chronic consumption is reported to elevate circulating ghrelin, and ghrelin is described as promoting adipose lipolysis while inhibiting insulin secretion [3]. The cited work investigated how ethanol modulates ghrelin production and disrupts nutrient sensing in ghrelin-secreting cells, using in vitro mechanistic approaches [3]. This is a cell-based study; the lipolysis statement is framed as part of the background rationale rather than as an endpoint measured in that experiment.

Erythropoietin and lipolysis in white and brown adipose tissue

EPO is best characterised as the principal regulator of erythrocyte production, acting on erythroid progenitors in fetal liver and adult bone marrow; mice lacking EPO or EPOR die in utero from severe anaemia [5]. Beyond haematopoiesis, EPO is reported to influence glucose and fat metabolism in adipose tissue, skeletal muscle and liver, and to enhance lipolysis while inhibiting lipogenic gene expression in white adipose tissue, brown adipose tissue and skeletal muscle [5]. The review frames these as non-haematopoietic actions of EPO; the evidence block does not specify which of the underlying experiments were animal versus human.

Omentin-1 and in vitro oocyte maturation via ERK1/2 and PRKAA1

Omentin-1 was reported to enhance in vitro maturation of porcine oocytes, increasing the proportion reaching metaphase II, progesterone levels, mitochondrial function and lipolysis, acting through extracellular signal-regulated kinase 1/2 and AMP-activated protein kinase alpha 1 (PRKAA1), with no observed effect on preimplantation embryo development [10]. This is an in vitro study in a porcine model; it does not establish a lipolysis effect in humans.

FGF21, central lactate uptake and systemic fat mobilisation in rats

FGF21 regulates lipid metabolism, and lactate has been proposed to act centrally on energy homeostasis. In male Wistar rats, central lactate uptake during exercise was examined for its contribution to hypothalamic FGF21 induction and sympathetic-driven lipolysis, and for whether central FGF21 contributes to exercise-induced fat oxidation [12]. This is an animal study; the findings are not directly transferable to human dosing or clinical use.

Myostatin and hormone-sensitive lipase in overweight and obese men

A randomised controlled trial assigned 36 overweight and obese men to upper-body combined training, lower-body combined training, or a non-exercising control group, with 10 weeks of combined resistance and aerobic training three times per week, and measured serum myostatin and HSL [7]. Myostatin is described as a myokine involved in skeletal muscle growth and adipose tissue metabolism, and HSL as a key enzyme in lipolysis and fat mobilisation [7]. This is a human trial, but the intervention is exercise rather than a peptide.

hCG and IGF-I in doping-control method development

hCG and IGF-I are both on the WADA list of banned molecules. Male athletes may use pharmaceutical hCG to stimulate testosterone production before competition, and IGF-I to stimulate muscle protein synthesis, promote glycogen storage and improve lipolysis [4]. The cited study is a technical note on a UHPLC-MS/MS method for analysing hCG and IGF-I from dried blood spots, described as preliminary [4]. The lipolysis reference here is contextual, not an experimental endpoint.

Sulforaphane and AMPK-centred lipid pathways

Sulforaphane is an isothiocyanate produced from glucoraphanin in cruciferous vegetables, not a peptide, but it appears in this literature because of its AMPK-centred mechanism. In cell and animal models, sulforaphane treatment was associated with ACC phosphorylation, inhibition of mTORC1-SREBP signalling, CPT-1-related fatty acid oxidation, PGC-1α/PPAR-α transcriptional regulation and ULK1-mediated lipophagy [1]. The review explicitly distinguishes pathway association from experimentally demonstrated AMPK dependence, noting that most studies measured AMPK phosphorylation without pharmacological or genetic confirmation [1].

Neu1, GCGR desialylation and hepatic metabolic regulation in old mice

Neuraminidase 1 (Neu1) removes sialic acid from glycoproteins and glycolipids and influences hepatic glycolipid metabolism. Liver-specific Neu1 knockout mice were constructed to examine liver glycolipid metabolism, and glucagon was used in HepG2 cells [2]. The work links hepatic Neu1 deficiency to metabolic dysregulation via GCGR desialylation-dependent cAMP-PKA signalling and inflammatory response in old mice [2]. This is an animal model with a cell-line component; it concerns hepatic glucose and bile acid regulation rather than a peptide therapeutic.

Canagliflozin and adipocyte-intrinsic lipid mobilisation

Canagliflozin, a sodium-glucose cotransporter 2 inhibitor rather than a peptide, was reported to promote 3T3-L1 preadipocyte differentiation while enhancing lipid mobilisation and thermogenesis, an AMPK/autophagy-dependent pro-adipogenic effect coupled with anti-obesity action [9]. This is a cell-model finding.

Depot-specific adipose differences in patients with obesity

Paired visceral and subcutaneous adipose tissue samples were collected from 22 patients with obesity undergoing elective Roux-en-Y surgery to compare depot function [11]. The study addresses fat cell expandability and depot-specific differences in humans [11]. It does not test a peptide.

Alpha ketoglutarate and surgical stress in older patients

A registered trial examines alpha ketoglutarate in the context of coronary artery bypass grafting, a procedure performed in approximately 400,000 patients in the United States each year, and the massive surgical stress response it invokes, including a 33-fold rise in systemic epinephrine and a 3-fold rise in norepinephrine [6]. Alpha ketoglutarate is a metabolite, not a peptide, and the entry describes trial rationale rather than lipolysis endpoints.

Diet, hepatic transcriptomics and lipidomics in pre-diabetes

A registered study examines diet impact on hepatic transcriptomics and lipidomics in pre-diabetes, in a context where NAFLD affects 25% to 30% of the global population and nearly one third of North America, with a minimum histologic criterion of greater than 5 percent hepatic steatosis [8]. This is a dietary intervention study, not a peptide study.

If you are reading this for personal health reasons

The compounds discussed here are sold for laboratory research use only, and we do not provide dosing, administration or medical guidance of any kind. Nothing on this page is a recommendation to use any compound, and no outcome is promised or implied. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp